Molecular Partners AG Files 6-K Announcing Press Release
Ticker: MOLN · Form: 6-K · Filed: Jun 11, 2024 · CIK: 1745114
Sentiment: neutral
Topics: filing, press-release
Related Tickers: MPTL
TL;DR
MPTL filed a 6-K on 6/11/24, attaching a press release. Check the release for news.
AI Summary
On June 11, 2024, Molecular Partners AG filed a Form 6-K, announcing the issuance of a press release dated the same day. This press release is attached as Exhibit 99.1 to the filing and is incorporated by reference. The filing itself does not contain substantive new information beyond the announcement of the press release.
Why It Matters
This filing indicates that Molecular Partners AG has issued a new press release, which may contain important updates for investors regarding the company's operations or strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and primarily serves to attach an exhibit (a press release), rather than disclosing new material financial or operational information.
Key Players & Entities
- Molecular Partners AG (company) — Registrant
- June 11, 2024 (date) — Date of press release and filing
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report that Molecular Partners AG issued a press release on June 11, 2024, and to attach that press release as Exhibit 99.1.
What is the filing date of this report?
The filing date of this report is June 11, 2024.
What exhibit is attached to this Form 6-K?
Exhibit 99.1, a press release dated June 11, 2024, is attached to this Form 6-K.
Does Molecular Partners AG file annual reports under Form 20-F or 40-F?
Molecular Partners AG indicates it files annual reports under cover of Form 20-F.
Where is Molecular Partners AG headquartered?
Molecular Partners AG's principal executive office is located at Wagistrasse 14, 8952 Zurich-Schlieren, Switzerland.
Filing Stats: 170 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-06-11 10:16:45
Filing Documents
- f6k_061124.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 13KB
- 0001171843-24-003385.txt ( ) — 17KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Molecular Partners AG (Registrant) Date: June 11, 2024 /s/ PATRICK AMSTUTZ Patrick Amstutz Chief Executive Officer